Alzheimer’s disease (AD) is the most common form of all dementias. Our aims are to implement a change in the way we routinely assess people presenting with AD symptoms and to predict the future onset of the disease through the use of biomarkers. Our second aim is to develop further advances in disease modifying medications to help stop the progression and prevent onset of AD.
Theme Lead: Dr Richard Dobson
- Transform the system to encourage participation of patients with AD at South London and Maudsley NHS Foundation Trust to improve patient experiences and outcomes.
- Identify biomarkers of AD to help accurately diagnose and predict disease onset and effective medications to stop the onset and progression.
- Develop disease modifying medications. We will conduct first-in-man clinical trials of treatments developed in our BRC labs. We will also conduct first-in-disease trials of medications that are currently used elsewhere in medicine to determine if these drugs could be an effective intervention for AD.